Detection of IL21R in human breast cancer using RNAscope 2.5 HD Brown Assay
Detection of IL21A in human ovarian cancer using RNAscope 2.5 HD Brown Assay
Simultaneous detection of CTLA4 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay
Simultaneous detection of LAG3 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay
Simultaneous detection of PD1 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay
The field of immuno-oncology (IO) and cancer immunotherapy has expanded rapidly in recent years with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches such as cancer vaccines and chimeric antigen receptor T-cell (CAR-T) therapy.
However, our understanding of the function of immune cells, as well as the interactions of different cell types, in the tumor microenvironment (TME) is still limited. New targets and modulators for cancer therapy in the TME continue to be discovered, yet the tools to investigate these in tumor tissue are often lacking. While immunohistochemistry (IHC) is the conventional method of choice, its use is often limited because of the lack of specific and sensitive antibodies.
The RNAscope® technology enables rapid and efficient detection of co-expression profiles of any target mRNAs, including checkpoint and cell-specific markers, with single-molecule sensitivity and high specificity in formalin-fixed paraffin-embedded (FFPE) tissues.
ACD study: Surveying expression of immune checkpoint markers in the tissue microenvironment
ACD conducted a study to analyze co-expression of 8 checkpoint markers in 60 Non-Small Cell Lung Carcinoma FFPE tissue. Figure 1 illustrates an example of co-detection of these markers in a sample. This study reveals a heterogeneous pattern of expression in different tumor tissues as well as intratumor heterogeneity within each tumor, and potential insight into combination therapies targeted against different checkpoint pathways. Study data and results are discuss in the webinar accessible below.
Figure 1: The manual RNAscope® 2.5 HD Duplex assay was used to detect expression of the immune checkpoint marker PD-L1 (green chromogen) and PD-1, PD-L2, CTLA4, LAG3, TIM3 or 4-1BB (red chromogen) in human NSCLC tumors sample. PD-L1 and PD-L2 are primarily expressed in the tumor region and co-expressed in the same tumor cells. CTLA4, 4-1BB, PD1, LAG3, and TIM3 are expressed primarily in the stromal regions. Arrows indicate cells co-expressing PD-L1 with LAG3, TIM3, or PD-L2.
Watch recorded webinar (June 30th, 2016) to learn more about the ACD study: Surveying expression of immune checkpoint markers in the tissue microenvironment, presented by Jeffrey Kim, Research Scientist at ACD.
Immune profiling the tumor microenvironment with RNA and protein biomarkers by fluorescence multiplex RNA in situ hybridization and immunohistochemistry.
Evaluation of the Expression of Immune Functional Markers in the Tumor Microenvrionment (TME)